Ann: Notice of Annual General Meeting/Proxy Form, page-52

Not true fattchoi. If you listen to her last interview she says:

In relation to HER-Vaxx: "I'm quite pleased to date (with) the data I'm privy to"; and
In relation to PD1-Vaxx: "We're just anxiously awaiting the patients to come on".

The last official announcement regarding PD1-Vaxx was that enrollment for this trial was to commence in August. So does her comment mean: "we're anxious because unfortunately as of early-October, no recruits in sight", or maybe "we have 5 recruits already and and anxiously awaiting the remaining 25" etc ...

What I'm saying is that shareholders and option holders would also like to be privy to the HER-Vaxx data and would probably like to know what "anxiously awaiting the patients to come on" translates to in terms of numbers.

I'm not damning her for converting options. I'm just saying that doing so - particularly when she's on the record as confirming she's privy to information that would be considered price sensitive by a reasonable investor (ok Hot Copper moderators?) means that she's doing so with information not available to other option holders.